![\"\"](\"https:\/\/static.stocktitan.net\/img\/icons\/Google_News_icon.svg\"){kind=icon}
<\/p>\n
\n
\n
<\/p>\n
\n
\n
\n
\n
\n
<\/p>\n
<\/p>\n
\n
\n See more from StockTitan in Google Search and AI answers.
\n Adds StockTitan as a preferred source \u00b7 opens Google
\n <\/p>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n 07\/27\/2026 – 07:00 AM
\n
\n
<\/p>\n
\nGrowth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030<\/p>\n
CAMBRIDGE, England–(BUSINESS WIRE)–
\nAstraZeneca:<\/p>\n
\nRevenue and EPS summary<\/p>\n
\n\u00a0<\/p>\n
\nH1 2026<\/p>\n
\n% Change<\/p>\n
\nQ2 2026<\/p>\n
\n% Change<\/p>\n
\n\u00a0<\/p>\n
\n$m<\/p>\n
\nActual<\/p>\n
\nCER1<\/p>\n
\n$m<\/p>\n
\nActual<\/p>\n
\nCER<\/p>\n
\n– Product Sales<\/p>\n
\n28,896<\/p>\n
\n8<\/p>\n
\n5<\/p>\n
\n14,510<\/p>\n
\n5<\/p>\n
\n4<\/p>\n
\n– Alliance Revenue<\/p>\n
\n1,699<\/p>\n
\n31<\/p>\n
\n29<\/p>\n
\n874<\/p>\n
\n34<\/p>\n
\n33<\/p>\n
\nProduct Revenue<\/p>\n
\n30,595<\/p>\n
\n9<\/p>\n
\n6<\/p>\n
\n15,384<\/p>\n
\n6<\/p>\n
\n5<\/p>\n
\nCollaboration Revenue<\/p>\n
\n77<\/p>\n
\n(6)<\/p>\n
\n(9)<\/p>\n
\n–<\/p>\n
\nn\/m<\/p>\n
\nn\/m<\/p>\n
\nTotal Revenue<\/p>\n
\n30,672<\/p>\n
\n9<\/p>\n
\n6<\/p>\n
\n15,384<\/p>\n
\n6<\/p>\n
\n5<\/p>\n
\nReported EPS ($)<\/p>\n
\n3.60<\/p>\n
\n4<\/p>\n
\n3<\/p>\n
\n1.61<\/p>\n
\n2<\/p>\n
\n(2)<\/p>\n
\nCore2 EPS ($)<\/p>\n
\n5.21<\/p>\n
\n12<\/p>\n
\n11<\/p>\n
\n2.63<\/p>\n
\n21<\/p>\n
\n18<\/p>\n
\nKey performance elements for H1 2026<\/p>\n
\n(Growth numbers at constant exchange rates)<\/p>\n
Total Revenue up 6%, with double-digit growth in Oncology and Rare Disease offsetting headwinds from Farxiga US loss of exclusivity and China volume-based procurement<\/p>\n
Core Operating profit and Core EPS increased 11%<\/p>\n
Interim dividend increased 3 cents to $1.06 per share (79.5 pence, 10.32 SEK)<\/p>\n
30 approvals in major regions since Q4 2025 results<\/p>\n
\nPascal Soriot, Chief Executive Officer, AstraZeneca, said:<\/p>\n
\n“In the first half we saw strong performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets, including in the US for Baxfendy, our first-in-class medicine for hypertension.<\/p>\n
\nWhile we are disappointed by the CARDIO-TTRansform outcome, we are on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks. We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months.<\/p>\n
\nWe continue to invest at pace in our transformative technologies, and in our commercial execution to bring our innovative medicines to patients around the globe and drive growth beyond 2030.”<\/p>\n
\nGuidance<\/p>\n
\nAstraZeneca reconfirms Total Revenue and Core EPS guidance3 for FY 2026 at CER, based on the average foreign exchange rates through 2025.<\/p>\n
\nTotal Revenue is expected to increase by a mid-to-high single-digit percentage<\/p>\n
\nCore EPS is expected to increase by a low double-digit percentage<\/p>\n
\nThe Core Tax rate is expected to be between 18-22%<\/p>\n
\nIf foreign exchange rates for July 2026 to December 2026 were to remain at the average rates seen in June 2026, it is anticipated that Total Revenue in FY 2026 would benefit from a low single-digit percentage positive impact (unchanged) compared to the performance at CER, and Core EPS growth would be broadly similar (unchanged) to the growth at CER.<\/p>\n
\nResults highlights<\/p>\n
\nTable 1: Milestones achieved since the prior results announcement<\/p>\n
\nPhase III and other registrational data readouts<\/p>\n
\nMedicine<\/p>\n
\nTrial<\/p>\n
\nIndication<\/p>\n
\nEvent<\/p>\n
\nImfinzi<\/p>\n
\nVOLGA<\/p>\n
\nMIBC not candidates for cisplatin<\/p>\n
\nPrimary endpoint met<\/p>\n
\nImfinzi<\/p>\n
\nEMERALD-2<\/p>\n
\nAdjuvant HCC<\/p>\n
\nPrimary endpoint not met<\/p>\n
\nImfinzi<\/p>\n
\nNILE<\/p>\n
\n1L bladder cancer<\/p>\n
\nPrimary endpoint met<\/p>\n
\nsone-ve<\/p>\n
\nCLARITY-Gastric01<\/p>\n
\n2L+ Cldn18.2+ gastric\/GEJ cancer<\/p>\n
\nPrimary endpoint met<\/p>\n
\nWainua<\/p>\n
\nCARDIO-TTRansform<\/p>\n
\nATTR-CM<\/p>\n
\nPrimary endpoint not met<\/p>\n
\nUltomiris<\/p>\n
\nTMA-313<\/p>\n
\nHSCT-TMA (adults)<\/p>\n
\nPrimary endpoint not met<\/p>\n
\nUltomiris<\/p>\n
\nALXN1210-MG-319<\/p>\n
\ngMG (paediatric)<\/p>\n
\nPrimary endpoint met<\/p>\n
\nRegulatory approvals<\/p>\n
\nMedicine<\/p>\n
\nTrial<\/p>\n
\nIndication<\/p>\n
\nRegion<\/p>\n
\nCalquence<\/p>\n
\nAMPLIFY<\/p>\n
\n1L CLL (fixed duration)<\/p>\n
\nJP<\/p>\n
\nDatroway<\/p>\n
\nTROPION-Breast02<\/p>\n
\n1L TNBC for patients where immunotherapy is not an option<\/p>\n
\nUS<\/p>\n
\nEnhertu<\/p>\n
\nDESTINY-Breast05<\/p>\n
\nHigh-risk HER2+ early breast cancer (post-neoadjuvant)<\/p>\n
\nUS<\/p>\n
\nEnhertu<\/p>\n
\nDESTINY-Breast11<\/p>\n
\nNeoadjuvant HER2+ Stage II or III breast cancer<\/p>\n
\nUS<\/p>\n
\nEnhertu<\/p>\n
\nDESTINY-PanTumor02 \/ DESTINY-Lung01 \/ DESTINY-CRC02<\/p>\n
\nHER2-positive solid tumours<\/p>\n
\nEU<\/p>\n
\nEtcamah (camizestrant)<\/p>\n
\nSERENA-6<\/p>\n
\nESR1m HR+ HER2- 1L locally advanced or metastatic
\n
breast cancer<\/p>\n
\nEU, JP<\/p>\n
\nImfinzi<\/p>\n
\nPOTOMAC<\/p>\n
\nNMIBC<\/p>\n
\nUS<\/p>\n
\nImfinzi<\/p>\n
\nMATTERHORN<\/p>\n
\nResectable gastric\/GEJ cancer<\/p>\n
\nJP<\/p>\n
\nOrphathys<\/p>\n
\nNCT04923932<\/p>\n
\n3L+ MET+ gastric\/GEJ cancer<\/p>\n
\nCN<\/p>\n
\nTruqap<\/p>\n
\nCAPItello-281<\/p>\n
\nPTEN-deficient mHSPC<\/p>\n
\nUS<\/p>\n
\nBaxfendy<\/p>\n
\nBaxHTN<\/p>\n
\nHypertension<\/p>\n
\nUS<\/p>\n
\nFasenra<\/p>\n
\nNATRON<\/p>\n
\nHypereosinophilic syndrome<\/p>\n
\nUS, EU, JP, CN<\/p>\n
\nRegulatory submissions or acceptances* in major regions<\/p>\n
\nMedicine<\/p>\n
\nTrial<\/p>\n
\nIndication<\/p>\n
\nRegion<\/p>\n
\nBaxfendy<\/p>\n
\nBaxHTN \/ Bax24 \/ BaxAsia<\/p>\n
\nHypertension<\/p>\n
\nJP<\/p>\n
\ntozorakimab<\/p>\n
\nOBERON \/ TITANIA \/ MIRANDA \/ PROSPERO<\/p>\n
\nCOPD<\/p>\n
\nEU, CN<\/p>\n
\nUltomiris<\/p>\n
\nI CAN<\/p>\n
\nIgAN<\/p>\n
\nUS, JP<\/p>\n
\nefzimfotase alfa<\/p>\n
\nMULBERRY \/ CHESTNUT \/ HICKORY<\/p>\n
\nHPP<\/p>\n
\nJP<\/p>\n
\n* US, EU and China regulatory entries in this table denote filing acceptance<\/p>\n
\nOther pipeline updates<\/p>\n
\nFor recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix document in the financial results section of the AstraZeneca investor relations website: www.astrazeneca.com\/investor-relations.html<\/a><\/p>\n \nTable 2: Key elements of financial performance: Q2 2026<\/p>\n \nFor the quarter<\/p>\n \u00a0<\/p>\n \nReported<\/p>\n \u00a0<\/p>\n \nChange<\/p>\n \u00a0<\/p>\n \nCore<\/p>\n \u00a0<\/p>\n \nChange<\/p>\n \u00a0 \n\u00a0<\/p>\n \nended 30 June<\/p>\n \u00a0<\/p>\n \n$m<\/p>\n \u00a0<\/p>\n \nAct<\/p>\n \u00a0<\/p>\n \nCER<\/p>\n \u00a0<\/p>\n \n$m<\/p>\n \u00a0<\/p>\n \nAct<\/p>\n \u00a0<\/p>\n \nCER<\/p>\n \u00a0 \n\u00a0<\/p>\n \nProduct Revenue<\/p>\n \u00a0<\/p>\n \n15,384<\/p>\n \u00a0<\/p>\n \n6<\/p>\n \u00a0<\/p>\n \n5<\/p>\n \u00a0<\/p>\n \n15,384<\/p>\n \u00a0<\/p>\n \n6<\/p>\n \u00a0<\/p>\n \n5<\/p>\n \u00a0 \n* See Tables 3, 7, 23, 24 and 25 for further details of Product Revenue, Product Sales and Alliance Revenue<\/p>\n \nCollaboration Revenue<\/p>\n \u00a0<\/p>\n \n–<\/p>\n \u00a0<\/p>\n \nn\/m<\/p>\n \u00a0<\/p>\n \nn\/m<\/p>\n \u00a0<\/p>\n \n–<\/p>\n \u00a0<\/p>\n \nn\/m<\/p>\n \u00a0<\/p>\n \nn\/m<\/p>\n \u00a0 \n* See Tables 4 and 26 for further details of Collaboration Revenue<\/p>\n \nTotal Revenue<\/p>\n \u00a0<\/p>\n \n15,384<\/p>\n \u00a0<\/p>\n \n6<\/p>\n \u00a0<\/p>\n \n5<\/p>\n \u00a0<\/p>\n \n15,384<\/p>\n \u00a0<\/p>\n \n6<\/p>\n \u00a0<\/p>\n \n5<\/p>\n \u00a0 \n* See Tables 5 and 6 for Total Revenue by Therapy Area and by region<\/p>\n \nGross Margin (%)<\/p>\n \u00a0<\/p>\n \n84<\/p>\n \u00a0<\/p>\n \n+1pp<\/p>\n \u00a0<\/p>\n \n–<\/p>\n \u00a0<\/p>\n \n84<\/p>\n \u00a0<\/p>\n \n+1pp<\/p>\n \u00a0<\/p>\n \n+1pp<\/p>\n \u00a0 \n+ Variations in Gross Margin can be expected between periods due to various factors, including fluctuations in foreign exchange rates, product seasonality and Collaboration Revenue \nR&D expense<\/p>\n \u00a0<\/p>\n \n4,053<\/p>\n \u00a0<\/p>\n \n14<\/p>\n \u00a0<\/p>\n \n13<\/p>\n \u00a0<\/p>\n \n3,662<\/p>\n \u00a0<\/p>\n \n6<\/p>\n \u00a0<\/p>\n \n5<\/p>\n \u00a0 \n* Core R&D: 24% of Total Revenue \nSG&A expense<\/p>\n \u00a0<\/p>\n \n5,651<\/p>\n \u00a0<\/p>\n \n16<\/p>\n \u00a0<\/p>\n \n14<\/p>\n \u00a0<\/p>\n \n4,050<\/p>\n \u00a0<\/p>\n \n7<\/p>\n \u00a0<\/p>\n \n4<\/p>\n \u00a0 \n* Core SG&A: 26% of Total Revenue \nOther operating income and expense4<\/p>\n \u00a0<\/p>\n \n152<\/p>\n \u00a0<\/p>\n \n92<\/p>\n \u00a0<\/p>\n \n93<\/p>\n \u00a0<\/p>\n \n152<\/p>\n \u00a0<\/p>\n \n>2x<\/p>\n \u00a0<\/p>\n \n>2x<\/p>\n \u00a0 \n+ Various partner milestones<\/p>\n \nOperating profit<\/p>\n \u00a0<\/p>\n \n3,164<\/p>\n \u00a0<\/p>\n \n(10)<\/p>\n \u00a0<\/p>\n \n(13)<\/p>\n \u00a0<\/p>\n \n5,158<\/p>\n \u00a0<\/p>\n \n12<\/p>\n \u00a0<\/p>\n \n10<\/p>\n \u00a0 \n\u00a0<\/p>\n \nOperating Margin (%)<\/p>\n \u00a0<\/p>\n \n21<\/p>\n \u00a0<\/p>\n \n-4pp<\/p>\n \n\u00a0<\/p>\n \n-4pp<\/p>\n \n\u00a0<\/p>\n \n34<\/p>\n \n\u00a0<\/p>\n \n+2pp<\/p>\n \n\u00a0<\/p>\n \n+2pp<\/p>\n \u00a0 \n\u00a0<\/p>\n \nNet finance expense<\/p>\n \u00a0<\/p>\n \n355<\/p>\n \u00a0<\/p>\n \n(4)<\/p>\n \u00a0<\/p>\n \n(8)<\/p>\n \u00a0<\/p>\n \n340<\/p>\n \u00a0<\/p>\n \n13<\/p>\n \u00a0<\/p>\n \n8<\/p>\n \u00a0 \n+ Lower interest income on short-term deposits \nTax rate (%)<\/p>\n \u00a0<\/p>\n \n10<\/p>\n \u00a0<\/p>\n \n-11pp<\/p>\n \n\u00a0<\/p>\n \n-11pp<\/p>\n \n\u00a0<\/p>\n \n15<\/p>\n \n\u00a0<\/p>\n \n-6pp<\/p>\n \n\u00a0<\/p>\n \n-6pp<\/p>\n \u00a0 \n\u2212 Benefit from adjustments to deferred tax assets, as a result of certain internal legal entity changes.<\/p>\n \n* Variations in the tax rate can be expected between periods<\/p>\n \nEPS ($)<\/p>\n \u00a0<\/p>\n \n1.61<\/p>\n \u00a0<\/p>\n \n2<\/p>\n \u00a0<\/p>\n \n(2)<\/p>\n \u00a0<\/p>\n \n2.63<\/p>\n \u00a0<\/p>\n \n21<\/p>\n \u00a0<\/p>\n \n18<\/p>\n \u00a0 \n\u00a0<\/p>\n \nFor dollar values in this table, the unit of change is percent. For Gross Margin, Operating Margin and Tax rate, the unit of change is percentage points (pp).<\/p>\n \n\u00a0<\/p>\n \nIn the table above, R&D expense, SG&A expense and Net finance expense are displayed as positive numbers. The plus and minus symbols next to comments denote the directional impact of the item being discussed. For example, a plus symbol next to a comment about an R&D item indicates that the item increased R&D expenditure relative to the prior year period.<\/p>\n \nCorporate and business development<\/p>\n \nDizal Pharmaceutical Co \nAstraZeneca will acquire worldwide rights to develop and commercialise Zegfrovy, which is approved in the US and China for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.<\/p>\n \nAstraZeneca will make an upfront payment to Dizal of $600m and additional payments of up to $900m upon achievement of specific development, regulatory and sales-related milestones. Additionally, Dizal will receive tiered royalties on the global sales of Zegfrovy. The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory clearances.<\/p>\n \nSino Biopharmaceutical \nSino Biopharmaceutical Limited is eligible to receive an upfront payment of $200m, with additional development, regulatory and sales milestones up to $1.9bn, as well as tiered royalties ranging up to double-digit percentages based on the annual net sales of TQC3721 products.<\/p>\n \nThe agreement is subject to customary closing conditions, including regulatory clearances.<\/p>\n \nSustainability highlights<\/p>\n \nIn July 2026, AstraZeneca hosted a call for investors to discuss the latest developments in its Sustainability strategy. A replay of the call is available on astrazeneca.com<\/a>.<\/p>\n \nReporting calendar<\/p>\n \nThe Company intends to publish its 9M and Q3 2026 results on 30 October 2026.<\/p>\n \nConference call<\/p>\n \nA conference call and webcast for investors and analysts will begin today, 27 July 2026, at 11:45 UK time. Details can be accessed via astrazeneca.com<\/a>.<\/p>\n \nNotes<\/p>\n Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2026 vs. 2025. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.<\/p>\n Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Tables 10 and 11 in the Financial Performance section of this document.<\/p>\n The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the Cautionary statements section regarding forward-looking statements at the end of this announcement.<\/p>\n Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, is recorded in Other operating income and expense in the Group’s financial statements.<\/p>\n \nTo read AstraZeneca’s H1 & Q2 2026 Financial Results press release in full, read here<\/a> .<\/p>\n View source version on businesswire.com: https:\/\/www.businesswire.com\/news\/home\/20260726929817\/en\/<\/a><\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n
\u2212 Pricing headwinds, including those driven by loss of exclusivity and VBP in China<\/p>\n
\n\u00a0<\/p>\n
\n
+ Increasing number of trials, and patients in those trials
\n
+ Investments in transformative technologies
\n
+ Addition of R&D projects from business development
\n
+ Positive data readouts for high value pipeline opportunities that have ungated large late-stage trials<\/p>\n
\n\u00a0<\/p>\n
\n
+ Investment to support ongoing and future launches<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n
\u2212 Reported Net finance expense benefitted from a lower discount unwind on contingent consideration liabilities<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n
In July 2026, AstraZeneca entered into an exclusive license agreement with Dizal Pharmaceutical Co (Dizal), Ltd for Zegfrovy (sunvozertinib), a novel oral irreversible EGFR inhibitor for patients with lung cancer.<\/p>\n
\n
In July 2026, AstraZeneca and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited, entered into an exclusive licence agreement for the development, manufacturing and commercialisation of CTTQ’s PDE3\/4 inhibitor, TQC3721, which is being developed for respiratory indications.<\/p>\n<\/p>\n